Adiponectin and visceral fat share a clinically important inverse relationship that lies at the heart of cardiometabolic health. Adiponectin, a hormone secreted by fat cells, paradoxically falls as visceral fat increases — and this suppression is linked to insulin resistance, type 2 diabetes, cardiovascular disease, and fatty liver disease. Understanding why visceral fat drives down adiponectin, how this affects metabolic health, and what practical steps can reverse the trend is increasingly relevant for both patients and clinicians. This article explores the science behind adiponectin and visceral fat, how visceral fat is assessed in UK clinical practice, and when to seek medical advice.

What Is Adiponectin and How Does It Affect the Body?

Adiponectin is a protein hormone produced by fat cells that enhances insulin sensitivity, suppresses inflammation, and promotes fatty acid oxidation; paradoxically, higher body fat — especially visceral fat — is associated with lower circulating adiponectin levels.

Adiponectin is a protein hormone secreted almost exclusively by adipose (fat) tissue, particularly by mature adipocytes — the specialised cells that store fat. Despite being produced by fat cells, adiponectin has a somewhat paradoxical relationship with body fat: individuals with higher levels of body fat, especially visceral fat, tend to have lower circulating adiponectin concentrations rather than higher ones.

In terms of its physiological role, adiponectin is associated with several important effects throughout the body:

• Insulin sensitisation: Adiponectin appears to enhance the body's response to insulin by activating key signalling pathways, particularly through AMP-activated protein kinase (AMPK), which promotes glucose uptake in muscle and may reduce hepatic glucose production.

• Anti-inflammatory action: It is associated with suppression of pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), potentially helping to dampen chronic low-grade inflammation.

• Lipid metabolism: Adiponectin is linked to promotion of fatty acid oxidation in skeletal muscle and the liver, and to lower circulating triglyceride levels.^[15]

• Cardiovascular associations: Observational and mechanistic studies suggest adiponectin may inhibit the adhesion of monocytes to endothelial cells, which could reduce early stages of atherosclerosis; however, these findings are largely mechanistic or associational and have not yet been confirmed in large human outcome trials.^[16]

Circulating adiponectin can be measured as total adiponectin or as specific molecular forms, including high-molecular-weight (HMW) adiponectin. Assay methods and reported fractions vary considerably between laboratories, and there is currently no standardised UK reference range. For this reason, adiponectin is not routinely measured in NHS clinical practice, and any numeric reference interval should be interpreted with caution. Women generally have higher levels than men, and levels tend to decline with age and increasing adiposity. Because of its wide-ranging metabolic and anti-inflammatory associations, adiponectin is increasingly recognised as a potential biomarker of cardiometabolic health, though its clinical utility in routine practice remains under investigation.

The Link Between Visceral Fat and Low Adiponectin Levels

Visceral fat suppresses adiponectin secretion via pro-inflammatory cytokines, tissue hypoxia, and hormonal interference; low adiponectin may in turn worsen insulin resistance and fat accumulation, creating a self-reinforcing metabolic cycle.

Visceral fat — the fat stored deep within the abdominal cavity, surrounding organs such as the liver, pancreas, and intestines — is metabolically distinct from subcutaneous fat (the fat stored just beneath the skin). Visceral adipose tissue is far more metabolically active and is strongly associated with suppressed adiponectin secretion, though the precise mechanisms are still being investigated and much of the supporting evidence comes from preclinical or observational human studies.

Several biological processes have been proposed to help explain this inverse relationship:

• Inflammatory signalling: Visceral fat releases high levels of pro-inflammatory cytokines, including TNF-α and IL-6, which are thought to directly inhibit adiponectin gene expression and secretion from adipocytes.^[11][12]

• Hypoxia within fat tissue: As visceral fat expands, areas of the tissue may become poorly oxygenated. This hypoxic environment has been shown in preclinical and some human studies to be associated with reduced adiponectin production.

• Hormonal interference: Elevated cortisol and insulin resistance — both commonly associated with excess visceral fat — are thought to further suppress adiponectin synthesis, though causality in humans remains incompletely established.

Importantly, the relationship appears to be bidirectional, based on experimental and observational evidence. Low adiponectin levels may themselves contribute to further fat accumulation and worsening insulin resistance, creating a self-reinforcing cycle that may be difficult to interrupt without deliberate lifestyle or pharmacological intervention.

Large observational studies and meta-analyses consistently demonstrate that individuals with central obesity — characterised by a large waist circumference — have significantly lower adiponectin levels compared to those with a healthy weight distribution. This association holds even when total body weight is similar, highlighting that where fat is stored matters as much as how much fat is present.

Health Risks Associated With Reduced Adiponectin Activity

Low adiponectin is observationally associated with type 2 diabetes, cardiovascular disease, and NAFLD/MASLD; it reflects broader metabolic dysfunction rather than acting as a proven independent cause of these conditions.

Low adiponectin levels, often observed alongside excess visceral fat, are associated with a cluster of serious cardiometabolic conditions. It is important to note that adiponectin is considered a biomarker of metabolic dysfunction rather than a proven direct cause of disease in isolation; its reduced activity reflects and may amplify underlying pathological processes, but the associations described below are largely observational.

Type 2 diabetes is among the most well-established associations. Without adequate adiponectin signalling, insulin sensitivity may deteriorate, hepatic glucose output may increase, and pancreatic beta-cell function may be impaired over time. Prospective studies have shown that low adiponectin levels are associated with an increased risk of developing type 2 diabetes, independently of other risk factors.^[13][14]

Cardiovascular disease is another significant concern. Reduced adiponectin activity is associated with:

• Endothelial dysfunction and increased arterial stiffness

• Higher levels of LDL cholesterol and triglycerides

• Elevated blood pressure

• Accelerated atherosclerosis

These are associations from observational research; a direct causal role for adiponectin in human cardiovascular outcomes has not been firmly established.

Non-alcoholic fatty liver disease (NAFLD) — now increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD) in international literature, though many UK NHS resources continue to use NAFLD — is also strongly associated with low adiponectin. The hormone is thought to normally suppress hepatic lipid accumulation and inflammation; observational data suggest that lower adiponectin levels are associated with greater hepatic fat deposition, which may progress to fibrosis or cirrhosis in some individuals. Assessment and management of NAFLD/MASLD in UK primary care is guided by NICE (NG49), which recommends risk stratification tools such as the FIB-4 score.

Additionally, emerging evidence suggests associations between low adiponectin and certain cancers (including colorectal and breast cancer), polycystic ovary syndrome (PCOS), and obstructive sleep apnoea, though these links require further research before firm clinical conclusions can be drawn. Overall, low adiponectin should be understood as part of a broader metabolic risk profile rather than an isolated finding.

How Visceral Fat Is Assessed in Clinical Practice in the UK

NHS clinicians use waist circumference as the primary proxy measure for visceral fat, with NICE (CG189) thresholds of ≥94 cm (men) and ≥80 cm (women) indicating increased cardiometabolic risk; lower thresholds apply for South Asian and certain other ethnic groups.

In routine NHS clinical practice, visceral fat is not directly measured in most patients. Instead, clinicians use proxy measures that are practical, cost-effective, and well-validated against metabolic risk. NICE guidance (CG189) and the NHS Health Check programme incorporate several of these tools.

Waist circumference is the most widely used clinical measure. NICE recommends the following thresholds as indicators of increased cardiometabolic risk:

• Men: Waist circumference ≥94 cm (increased risk) or ≥102 cm (high risk)

• Women: Waist circumference ≥80 cm (increased risk) or ≥88 cm (high risk)

For people of South Asian, Chinese, Japanese, and many other Asian backgrounds, visceral fat accumulation and associated metabolic risk can occur at smaller body sizes. NICE (PH46) recommends lower BMI thresholds for these groups (23 kg/m² for increased risk and 27.5 kg/m² for high risk, rather than the standard 25 and 30 kg/m²). The International Diabetes Federation consensus also suggests lower waist circumference cut-offs for many Asian groups (≥90 cm for men and ≥80 cm for women).^[17] Clinicians should apply appropriate thresholds based on individual ethnicity and clinical context.

Waist-to-height ratio is an additional tool endorsed in some NHS communications, with a ratio above 0.5 generally considered a marker of elevated risk. Waist-to-hip ratio is used by some clinicians but is less emphasised in current NICE guidance.

A note of caution: consumer body composition scales and devices that display a 'visceral fat rating' are not clinically validated for diagnostic purposes and should not be used to guide medical decisions.

For more precise quantification of visceral fat, imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI) can directly measure visceral adipose tissue volume. However, these are not recommended routinely for this purpose due to cost, radiation exposure (in the case of CT), and limited impact on everyday clinical management. Dual-energy X-ray absorptiometry (DEXA) scanning is sometimes used in research settings.

Blood tests — including fasting glucose, HbA1c, lipid profile, and liver function tests — are used alongside anthropometric measures to build a comprehensive picture of metabolic health, in line with the NHS Health Check programme offered to adults aged 40–74 in England.^[9]

Lifestyle Changes That May Improve Adiponectin and Reduce Visceral Fat

Aerobic exercise, resistance training, a Mediterranean-style diet, smoking cessation, and modest weight loss are all associated with raised adiponectin levels and reduced visceral fat, in line with NICE public health guidance.

The encouraging news is that adiponectin levels appear to be modifiable, and evidence consistently shows that targeted lifestyle changes can raise adiponectin concentrations whilst simultaneously reducing visceral fat. These changes align closely with NICE public health guidance on weight management and cardiovascular risk reduction.

Physical activity is one of the most effective interventions. Both aerobic exercise (such as brisk walking, cycling, or swimming) and resistance training have been associated with increased adiponectin levels, even in the absence of significant weight loss. Current NHS guidelines for adults recommend:

• At least 150 minutes of moderate-intensity aerobic activity per week, or 75 minutes of vigorous activity

• Muscle-strengthening activities on two or more days per week

Dietary modification plays an equally important role. Evidence supports the following approaches:

• Adopting a Mediterranean-style diet rich in vegetables, legumes, whole grains, oily fish, and olive oil, which has been associated with higher adiponectin levels in observational studies

• Reducing intake of ultra-processed foods, refined carbohydrates, and added sugars

• Adequate intake of omega-3 fatty acids (found in oily fish and flaxseed) has been associated with adiponectin levels in some studies, though the evidence is mixed and omega-3 supplementation is not specifically recommended for this purpose

• Limiting alcohol intake in line with UK Chief Medical Officers' low-risk drinking guidelines (no more than 14 units per week, spread over three or more days, with several alcohol-free days)^[5][6]

Smoking cessation is also important: smoking is associated with lower adiponectin levels and significantly increases cardiometabolic risk. Support is available through NHS Stop Smoking services.

Weight loss, even modest reductions of 5–10% of body weight, has been shown to meaningfully increase adiponectin levels and reduce visceral fat volume. Structured weight management programmes (Tier 2 and Tier 3 services) are available through NHS referral for eligible individuals, in line with NICE guidance.

Sleep quality and stress management are also relevant, as poor sleep and chronic psychological stress elevate cortisol, which is associated with suppressed adiponectin. Addressing these factors holistically, rather than focusing on a single intervention, is likely to yield the greatest benefit.

When to Seek Medical Advice About Visceral Fat and Metabolic Health

Speak to your GP if your waist circumference exceeds NICE thresholds, you have a high BMI, or you have risk factors such as a family history of type 2 diabetes; seek same-day urgent care if you experience symptoms of significant hyperglycaemia.

Many people are unaware that they carry excess visceral fat, as it is not always visible externally and does not necessarily correlate with overall body weight. Knowing when to seek professional assessment is therefore important for early identification and prevention of serious metabolic conditions.

You should consider speaking to your GP or practice nurse if:

• Your waist circumference exceeds the NICE thresholds outlined above

• You have been told you have a high BMI (≥25 kg/m² for most adults, or lower thresholds for South Asian and certain other ethnic groups)

• You have a family history of type 2 diabetes, cardiovascular disease, or fatty liver disease

• You have been diagnosed with PCOS, hypertension, or dyslipidaemia, all of which are associated with visceral fat accumulation and low adiponectin

• You experience symptoms that may suggest insulin resistance or metabolic dysfunction, such as persistent fatigue, increased thirst, or difficulty losing weight despite lifestyle efforts

Seek urgent same-day medical attention if you experience symptoms that may indicate significant hyperglycaemia, including excessive thirst, very frequent urination, unexplained weight loss, drowsiness, vomiting, or breathing difficulties. These symptoms require prompt assessment and should not be left until a routine appointment.

Your GP can arrange relevant investigations, including fasting blood glucose, HbA1c, a full lipid profile, and liver function tests. In the UK, an HbA1c of 42–47 mmol/mol indicates a high risk of developing type 2 diabetes (sometimes called prediabetes), whilst an HbA1c of 48 mmol/mol or above is used to diagnose type 2 diabetes.^[4] People with an HbA1c in the 42–47 mmol/mol range may be eligible for referral to the NHS Diabetes Prevention Programme (NDPP), which offers structured support to reduce the risk of progression to type 2 diabetes.^[4] If appropriate, referral to a dietitian, structured weight management programme (Tier 2 or Tier 3), or specialist metabolic clinic may also be offered.

It is worth noting that adiponectin is not routinely measured in NHS clinical practice at present, as assay methods vary, reference intervals are not standardised across UK laboratories, and clinical decision thresholds have not been formally adopted into UK guidelines. However, research into its use as a clinical biomarker is ongoing.

If you are concerned about your metabolic health, the NHS Health Check — available free to adults aged 40–74 in England — is an excellent starting point.^[9] Early intervention, guided by a healthcare professional, offers the best opportunity to reduce long-term risk and improve overall wellbeing.

Frequently Asked Questions